How Weight Loss Treatments — Including GLP-1 Peptide Drugs Like Semaglutide — Affect Blood Pressure

What the researchers found

The review covers the blood pressure effects of all major approved obesity therapies. GLP-1 receptor agonists (liraglutide and semaglutide) and tirzepatide — peptide-based therapies — are among the treatments examined for their impact on hypertension. The shared pathophysiology linking obesity and hypertension includes overactivity of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system, insulin resistance, and disruption of the leptin pathway.

The review presents clinical evidence for how each therapy modifies blood pressure, positioning weight loss as a dual-benefit strategy for managing both obesity and hypertension simultaneously.

Why it matters

With obesity and hypertension both at epidemic levels globally, treatments that address both conditions simultaneously offer significant clinical value. GLP-1 receptor agonists and tirzepatide — all peptide-based drugs — have become blockbuster medications for weight loss. Understanding their blood pressure effects helps clinicians choose the most appropriate therapy for patients who have both conditions, potentially reducing the need for separate antihypertensive medications.

How the study worked

This is a narrative review article that compiles and synthesizes clinical trial data on the blood pressure effects of approved obesity therapies. It examines pharmacological treatments (phentermine/topiramate, orlistat, naltrexone/bupropion, liraglutide, semaglutide, tirzepatide) and bariatric surgery.

What this study cannot tell us

As a narrative review, it may not capture all available literature systematically. The abstract does not report specific blood pressure reduction numbers for each therapy, making it difficult to compare magnitudes of effect. The review covers approved therapies as of 2024 and may not include emerging agents. Individual patient variability in blood pressure response to weight loss treatments is acknowledged but cannot be fully addressed in a review format.

How to read the evidence

This is a narrative review synthesizing clinical data from multiple trials. It provides a broad overview but does not conduct a systematic search or meta-analysis, so evidence strength depends on the underlying studies it summarizes.

When this study was published

Published in 2024, this review captures the current landscape of obesity pharmacotherapy including the latest GLP-1 agonists and tirzepatide, making it timely and relevant to current clinical practice.

The bigger picture

This review reflects the growing recognition that obesity and cardiovascular risk factors like hypertension cannot be treated in isolation. The emergence of peptide-based GLP-1 receptor agonists has transformed obesity treatment, and their cardiovascular benefits — including blood pressure reduction — are increasingly seen as a key advantage over older weight loss drugs. This aligns with the broader shift toward viewing peptide therapeutics as multi-system medications rather than single-target drugs.

Questions still open

• Do GLP-1 receptor agonists lower blood pressure independently of their weight loss effects, or is the blood pressure reduction entirely weight-mediated?
• Which approved weight loss therapy provides the greatest blood pressure reduction per kilogram of weight lost?
• Could combining a GLP-1 agonist with a traditional antihypertensive allow dose reduction of either medication?

Common questions

Read the original research

Weight Loss Therapies and Hypertension Benefits.

Biomedicines, 12(10)

Citation

Katsi, Vasiliki; Manta, Eleni; Fragoulis, Christos; Tsioufis, Konstantinos. (2024). Weight Loss Therapies and Hypertension Benefits.. Biomedicines, 12(10). https://doi.org/10.3390/biomedicines12102293